UPCC 19418: A Phase 1/2a Dose-Finding Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma
-
- STATUS
- Enrolling By Invitation
-
- participants needed
- 10
Summary
Multicenter, open-label study of PT-112 in patients with relapsed/refractory MM. The study will be conducted in two parts. The first part of the study involves dose-escalation, in which successive cohorts of patients will receive escalating doses of PT-112 until the maximum tolerated dose (MTD) is reached. The second part of the study involves treatment of an expansion cohort to confirm the tolerability of treatment at the recommended dose and evaluate evidence of treatment efficacy. All patients in the expansion cohort will be tested for genetic alterations in an effort to identify potential biomarkers for response to PT-112 treatment.
Details
| Condition | myeloma |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | 03288480 |
| Last Modified on | 19 February 2024 |
Eligibility
How to participate?
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.